Skip to content

A prospective randomized controlled trial for Yan's Jiangzhi Decoction Combined with atorvastatin in the treatment of dyslipidemia complicated with carotid atherosclerosis

A prospective randomized controlled trial for Yan's Jiangzhi Decoction Combined with atorvastatin in the treatment of dyslipidemia complicated with carotid atherosclerosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003687
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to the diagnosis of dyslipidemia with carotid atherosclerosis and / or plaque; 2. TCM syndrome differentiation belongs to Spleen Qi weakness, phlegm and blood stasis block; 3. Aged 18-70 years; 4. Although taking lipid-lowering drugs, the drug has been stopped for more than 2 weeks, and the blood lipid level still reaches the "rising" standard; 5. Patients are informed and sign informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Familial hyperlipidemia; 2. Simple decrease of HDL; 3. Secondary hyperlipidemia caused by drugs or other diseases; 4. Unstable angina pectoris, acute myocardial infarction, cerebrovascular accident, or PCI in recent three months; 5. Patients with heart failure and cardiac function NYHA >= class III; complicated with severe arrhythmia (such as frequent premature ventricular contractions, ventricular tachycardia, fast atrial fibrillation, etc.); 6. Uncontrolled grade 3 hypertension; 7. Body mass index (BMI)> 31; 8. Heparin, thyroxine and other drugs affecting blood lipid metabolism are being used; 9. Serious or unstable heart, liver, kidney, endocrine, blood and other medical diseases; 10. Mental illness or alcohol, drug dependence, cancer, diabetes; 11. Moderate and severe liver damage, moderate and severe abnormal liver function; 12. Allergic constitution, lactation, pregnant women, plan to get pregnant during the trial or to make their spouse pregnant; 13. Participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
blood fat;

Secondary

MeasureTime frame
Carotid ultrasound;High density lipoprotein;total cholesterol;triglyceride;

Countries

China

Contacts

Public ContactLiu Jun

Department of Traditional Chinese Medicine, Shanghai Tenth People's Hospital

liujune2011@163.com+86 13816951240

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026